Brain Mapping Unit, Department of Psychiatry, Behavioural and Clinical Neuroscience Institute, University of Cambridge, UK; School of Psychology and Psychiatry, Monash University, Australia; New Medicines, UCB Pharma, Belgium.
Department of Psychiatry, University of Illinois at Chicago, Chicago, USA; Mental Health Service Line, Jesse Brown VA Medical Center, Chicago, USA.
Curr Opin Pharmacol. 2014 Feb;14:54-61. doi: 10.1016/j.coph.2013.11.009. Epub 2013 Dec 8.
Functional imaging methods such as fMRI have been widely used to gain greater understanding of brain circuitry abnormalities in CNS disorders and their underlying neurochemical basis. Findings suggest that: (1) drugs with known clinical efficacy have consistent effects on disease relevant brain circuitry, (2) brain activation changes at baseline or early drug effects on brain activity can predict long-term efficacy; and (3) fMRI together with pharmacological challenges could serve as experimental models of disease phenotypes and be used for screening novel drugs. Together, these observations suggest that drug related modulation of disease relevant brain circuitry may serve as a promising biomarker/method for use in drug discovery to demonstrate target engagement, differential efficacy, dose-response relationships, and prediction of clinically relevant changes.
功能成像方法,如 fMRI,已被广泛用于更深入地了解中枢神经系统疾病中的大脑回路异常及其潜在的神经化学基础。研究结果表明:(1)具有已知临床疗效的药物对疾病相关的大脑回路具有一致的影响;(2)基线时的大脑激活变化或药物对大脑活动的早期影响可以预测长期疗效;(3)fMRI 结合药理学挑战可以作为疾病表型的实验模型,用于筛选新型药物。总之,这些观察结果表明,药物对疾病相关大脑回路的调节可能成为药物发现中一种有前途的生物标志物/方法,用于证明靶点结合、疗效差异、剂量反应关系以及预测临床相关变化。